olutasidenib olutasidenib olutasidenib, sold under the brand name rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia. olutasidenib is an isocitrate dehydrogenase-1 (idh1) inhibitor. it is taken by mouth. olutasidenibclinical datatrade namesrezlidhiaother namesft-2102license data us dailymed: olutasidenib routes ofadministrationby mouthatc codenonelegal statuslegal status us: ℞-only identifierscas number1887014-12-1pubchem cid118955396iuphar/bps10319drugbankdb16267chemspider72380144unii0t4imt8s5zkeggd12483chemblchembl4297610pdb ligandpwv (pdbe, rcsb pdb)chemical and physical dataformulac18h15cln4o2molar mass354.79 g·mol−13d model (jsmol)interactive image smiles c(nc1=cc=c(c#n)n(c)c1=o)c1=cc2=c(nc1=o)c=cc(cl)=c2 inchi inchi=inchi=1s/c18h15cln4o2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21h,1-2h3,(h,22,24)/t10-/m0/s1key:neqywyxgtjdakr-jtqlqieisa-n the most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis. olutasidenib was approved for medical use in the united states in december 2022. medical uses olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (idh1) mutation as detected by an fda-approved test. society and culture names olutasidenib is the international nonproprietary name.